Dr. Clemens Fischer

I am the founder and CEO of FUTRUE, an international healthcare group comprising over 20 independent, agile, and highly specialized companies. FUTRUE operates at the forefront of healthcare innovation, with a mission to revolutionize the industry by addressing unmet medical needs and improving patient outcomes through cutting-edge solutions. Our diverse portfolio spans several key areas of healthcare: Innovative Pain Therapeutics (Vertanical) FUTRUE is one of the leading companies in the development of groundbreaking pain therapies. We focus on novel mechanisms of action and advanced formulations to address chronic pain conditions, providing new hope to patients with unmet needs in this critical area of healthcare. Gut Health and Microbiome Research (Synformulas, Kijimea) We are pioneers in the field of microbiome-based therapies, recognizing the critical role of gut health in overall well-being. Synformulas develops probiotic and microbiome-focused solutions that target a variety of conditions, including gastrointestinal disorders, immune modulation, and mental health. Consumer Health (PharmaSGP) Through our consumer health subsidiaries (PharmaSGP, Restaxil), we provide evidence-based wellness and nutritional products that empower individuals to take charge of their health. This includes non prescription-drugs, supplements, and functional foods designed to support a balanced and active lifestyle. Pharmaceutical Development (Futrue Research & Sciences) We specialize in the research and development of innovative medicines,. Our work includes the exploration of new active ingredients, as well as the enhancement of existing therapies to improve efficacy and patient adherence. Our vision is to cut the development time of new drugs by half, enabling faster access to life-changing therapies for patients in need. Cannabinoid-Based Medicine (Vertanical) As a leader in the emerging field of cannabinoid therapeutics, FUTRUE develops pharmaceutical-grade cannabis-based treatments for a variety of medical conditions, including chronic pain, inflamatory bowel diseases etc.. Education and Advocacy (EMCM) With our international pharma media agency EMCM, managing an annual gross media volume exceeding €400 million, we established one of the leading direct-to-patient agencies. Our vision is to fundamentally transform communication with healthcare professionals and patients, raising awareness about critical health issues and advocating for policy changes that facilitate medical progress and patient well-being.